Computational analysis of fusion protein of anti-HER2 scFv and alpha luffin
A new immunotoxin protein for HER2 positive cancers
DOI:
https://doi.org/10.1590/s2175-97902022e20527Keywords:
Cancer, Targeted therapy, Fusion protein, Molecular dynamics, ImmunotoxinAbstract
The present study deals with the computational design and analysis of a novel fusion protein based on a single chain variable fragment that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) in breast cancer cells. Alpha luffin, a small ribosome inactivating protein (RIP), was attached to the anti-HER2 antibody fragment. I-TASSER modeling provided the full-length structure of the fusion protein. Molecular docking evaluated the molecular interactions of the complementarity-determining regions of designed fusion protein to HER2. Energy minimization and molecular dynamics simulations were conducted to refine the complexes. RMSD plot revealed reasonable stability of the fusion protein during the simulation. The free binding energy profile of complexes affirmed a favorable binding affinity of proteins in complex with HER2 using molecular mechanics Poisson-Boltzmann surface area (G-MMPBSA) algorithm. In general, this approach looks promising in the development of new fusion proteins in terms of immunotoxins with appropriate cytotoxicity.
Downloads
References
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19-25.
Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 2012;26(3):447-81.
Akbari B, Farajnia S, Ahdi Khosroshahi S, Safari F, Yousefi M, Dariushnejad H, et al. Immunotoxins in cancer therapy: Review and update. Int Rev Immunol. 2017;36(4):207-19.
Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J. Immunotoxin: A new tool for cancer therapy. Tumour Biol. 2017;39(2):1010428317692226.
Baldi A. Computational approaches for drug design and discovery: An overview. Sys Rev Pharm. 2010;1(1):99-105.
Baran D, Pszolla MG, Lapidoth GD, Norn C, Dym O, Unger T, et al. Principles for computational design of binding antibodies. Proc Natl Acad Sci USA. 2017;114(41):10900-5.
Barkhordari F, Sohrabi N, Davami F, Mahboudi F, Garoosi YT. Cloning, expression and characterization of a HER2-alpha luffin fusion protein in Escherichia coli Prep Biochem Biotechnol. 2019;49(8):759-66.
Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science. 2009;323(5921):1610-4.
Chen F, Liu H, Sun H, Pan P, Li Y, Li D, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. Phys Chem Chem Phys. 2016;18(32):22129-39.
Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511-9.
DeLano WL. The PyMOL molecular graphics system. http://www.pymol.org, 2002.
Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol. 2010;38(5):230-49.
Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. 2003;9(7):2837-48.
Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel). 2011;3(7):848-83.
Eisenberg D, Lüthy R, Bowie JU. VERIFY 3D: Assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997;277:396-404.
FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer. Int J Med Microbiol. 2004;293(7-8):577-82.
Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In: Walker, JM, editor. The proteomics protocols handbook. Totowa, NJ: Humana Press; 2005;571-607.
Guan M, Zhou YP, Sun JL, Chen SC. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169.
Guruprasad K, Reddy BB, Pandit MW. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng. 1990;4(2):155-61.
Kumar TA. CFSSP: Chou and Fasman secondary structure prediction server. Wide Spectrum. 2013;1(9):15-9.
Kumari R, Kumar R, Open Source Drug Discovery Consortium, Lynn A. g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54(7):1951-62.
Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157(1):105-32.
Laskowski RA and Swindells MB. ‘LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model . 2011;51(10):2778-86.
Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283-91.
Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins (Basel) . 2010;2(11):2645-62.
Liu SL, He W, Wang RP, Li Z, Wu J, Zhao Y, et al. Effects of recombinant hIL-2-Luffin P1 immunotoxin combining with arotinoid ethylester on the proliferation and apoptosis of Hut-78 cells. Mol Cell Toxicol. 2012;8:335-42.
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.
Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12(6):719-39.
Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei). 2015;5(4):19.
Palumbo MO, Kavan P, Miller W, Panasci L, Assouline S, Johnson N, et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front. Pharmacol. 2013;4:57.
Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725-38.
Schrot J, Weng A, Melzig MF. Ribosome-inactivating and related proteins. Toxins (Basel) . 2015;7(5):1556-615.
Shan L, Liu Y, Wang P. Recombinant immunotoxin therapy of solid tumors: challenges and strategies. J Basic Clin Med. 2013;2(2):1-6.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
Tong CW, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front Oncol. 2018;8:227.
van Zundert GC, Rodrigues JP, Trellet M, Schmitz C, Kastritis PL, Karaca E, et al. The HADDOCK2. 2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol . 2016;428(4):720-5.
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237-51.
Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server issue):W407-10.
Xu J, Zhang Y. How significant is a protein structure similarity with TM-score= 0.5?. Bioinformatics. 2010;26(7):889-95.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Funding data
-
Pasteur Institute of Iran
Grant numbers 996
